Pharvaris N.V. (9EN.F)
- Previous Close
14.00 - Open
14.00 - Bid 14.20 x --
- Ask 15.00 x --
- Day's Range
12.70 - 14.20 - 52 Week Range
10.20 - 22.80 - Volume
540 - Avg. Volume
9 - Market Cap (intraday)
794.126M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.48 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
pharvaris.comRecent News: 9EN.F
View MorePerformance Overview: 9EN.F
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9EN.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9EN.F
View MoreValuation Measures
Market Cap
782.94M
Enterprise Value
503.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.85
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.88%
Return on Equity (ttm)
-52.20%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-152.54M
Diluted EPS (ttm)
-2.48
Balance Sheet and Cash Flow
Total Cash (mrq)
236.5M
Total Debt/Equity (mrq)
0.33%
Levered Free Cash Flow (ttm)
-84.15M